MC 2
Research type
Research Study
Full title
UNDERSTANDING THE MOLECULAR PATHWAYS UNDERLYING DRUG RESPONSE AND RESISTANCE IN EARLY CLINICAL TRIALS THROUGH TUMOUR MOLECULAR CHARACTERISATION
IRAS ID
277366
Contact name
Johann De Bono
Contact email
Sponsor organisation
The Institute of Cancer Research
Duration of Study in the UK
5 years, 9 months, 30 days
Research summary
Research has shown that cancer cells make use of key genetic changes (mutations) to ‘switch on’ their growth, allow them to spread to other parts of the body and enable their survival. The aim of this study is to attempt to find altered genetic ‘switches’ in patient cancer cells and to try to use this information to evaluate what happens to these genetic switches over time. This could potentially enable the Drug Development Unit to match patients to trials and help to understand why some patients respond well to drugs that are currently being studied in clinical trials at the Royal Marsden Hospital.
REC name
London - Surrey Research Ethics Committee
REC reference
20/PR/0642
Date of REC Opinion
9 Feb 2021
REC opinion
Further Information Favourable Opinion